0001549595-24-000008.txt : 20240130 0001549595-24-000008.hdr.sgml : 20240130 20240130185258 ACCESSION NUMBER: 0001549595-24-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240130 FILED AS OF DATE: 20240130 DATE AS OF CHANGE: 20240130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hansen Gwenn CENTRAL INDEX KEY: 0001817160 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39398 FILM NUMBER: 24580069 MAIL ADDRESS: STREET 1: C/O NURIX THERAPEUTICS, INC. STREET 2: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nurix Therapeutics, Inc. CENTRAL INDEX KEY: 0001549595 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270838048 STATE OF INCORPORATION: DE FISCAL YEAR END: 1130 BUSINESS ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: (415) 660-5320 MAIL ADDRESS: STREET 1: 1700 OWENS STREET, SUITE 205 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: Nurix, Inc. DATE OF NAME CHANGE: 20120509 4 1 wk-form4_1706658767.xml FORM 4 X0508 4 2024-01-30 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817160 Hansen Gwenn C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Scientific Officer 0 Common Stock 2024-01-30 4 M 0 3207 0 A 36736 D Common Stock 2024-01-30 4 M 0 2000 0 A 38736 D Common Stock 2024-01-30 4 S 0 2334 7.9902 D 36402 D Restricted Stock Units 0 2024-01-30 4 M 0 3207 0 D Common Stock 3207 25654 D Restricted Stock Units 0 2024-01-30 4 M 0 2000 0 D Common Stock 2000 18000 D The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $7.93 and the highest price at which shares were sold was $8.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting. RSUs do not expire; they either vest or are canceled prior to the vest date. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting. /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen 2024-01-30